Current status of biomarkers in head and neck cancer

Steven S. Chang, Joseph Califano

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


As our understanding of HNSCC increases so has biomarker development. HPV16 integration is a significant marker of favorable prognosis and response to therapy for HNSCC. EGFR-amplification and overexpression is a poor-prognostic indicator. For premalignant lesions, LOH of 3p&9p21 loci confers an elevated risk of malignant transformation. As molecular targets are identified, these will be candidates for biomarkers for detection, diagnosis, prognosis, and therapy. Validation of these biomarkers requires demonstration of independence of significance beyond known biomarkers.

Original languageEnglish (US)
Pages (from-to)640-643
Number of pages4
JournalJournal of Surgical Oncology
Issue number8
StatePublished - Jun 15 2008


  • EGFR
  • HPV
  • LOH
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Current status of biomarkers in head and neck cancer'. Together they form a unique fingerprint.

Cite this